Search

Due to the unavoidable problem of aliasing, color flow signals from high blood flow velocities cannot be measured directly by conventional color Doppler. A new technology termed Quantitative Un-Aliased Speed Algorithm Recognition (Quasar) has been developed to overcome this limitation. Employing this technology, we used transesophageal color Doppler echocardiography to investigate whether the velocities detected by the Quasar would correlate with those obtained by continuous-wave Doppler both in vitro and in vivo. In the in vitro study, a 5.0 MHz transesophageal transducer of a Kontron Sigma 44 color Doppler flow system was used. Fourteen different peak velocities calculated and recorded by color Doppler-guided continuous-wave Doppler were randomly selected. In the clinical study, intraoperative transesophageal echocardiography was performed using the same transducer 18 adults (13 aortic valve stenosis, 2 aortic and 2 mitral stenosis, 2 hypertrophic obstructive cardiomyopathy and 1 mitral valve stenosis). Following each continuous-wave Doppler measurement, the Quasar was activated, and a small Quasar marker was placed in the brightest area of the color flow jet to obtain the maximum mean velocity readout. The maximum mean velocities measured by Quasar closely correlated with maximum peak velocities obtained by color flow guided continuous-wave Doppler in both in vitro (0.53 to 1.65 m/s, r = 0.99) and in vivo studies (1.50 to 6.01 m/s, r = 0.97). We conclude that the new Quasar technology can accurately measure high blood flow velocities during transesophageal color Doppler echocardiography. This technique has the potential of obviating the need for continuous-wave Doppler.

The commercially manufactured contrast agents, Echovist and Albunex, were compared with sonicated conventional agents, indocyanine green, 29% renografin-60, 0.9% normal saline and 25% mannitol in their ability to enhance color Doppler flow signals. In a pneumatically regulated pulsatile flow system, a glycerine, saline (0.9%) and sand (5 microns particle size) solution was imaged using a 2.5 MHz phased-array transducer. Four different flow velocities (0.40, 0.35, 0.30 and 0.25 m/s) as measured by color Doppler guided pulse Doppler were utilized. All color Doppler settings were kept constant throughout the study. Utilizing a power injector, four different volumes (1.0, 1.5, 2.0 and 2.5 mL) of each contrast agent were injected into the flow medium at various transducer angles (20, 30, 40 and 60 degrees) and various distances from the transducer (3.38, 5.5, 6.76 cm). For Echovist and Albunex, several concentrations varying from 2% to 100% were used. Keeping instrument settings constant, color flow areas obtained before and after each contrast injection were planimeterized and the percent increase in the color flow area computed and compared. At full (100%) concentration, 20 degrees transducer angle and a flow velocity of 0.40 m/s, the maximum increase in the color flow area was 568%, 251%, 180%, 110%, 71%, and 38% for Echovist, Albunex, sonicated indocyanine green, renografin, normal saline and mannitol, respectively. However, a significant reduction in the degree of color flow enhancement was observed, with decreases in the concentration of these agents, and increases in the Doppler beam incident angle or distance from the transducer. Increasing the flow velocity of the medium into which contrast was injected did not produce significant changes in the contrast enhancement effect for all agents except Echovist. Increasing the injection volume significantly increased the color flow area for sonicated agents but not for Echovist or Albunex. This preliminary in vitro study shows that the commercially manufactured contrast agents, Echovist and Albunex, are much superior to sonicated conventional contrast agents in the enhancement of color Doppler flow signals. Of the sonicated agents, indocyanine green had the best enhancement capability.